Critical Appraisal of Primary Systemic Endocrine Therapy in Receptor-Positive Postmenopausal Breast Cancer: An Update

Publisher： Karger

E-ISSN： 2296-5262|29|5|210-217

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.29, Iss.5, 2006-05, pp. : 210-217

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunohistochemical Detection of Breast Cancer Stem Cells in Hormone Receptor-Positive Breast Cancer and Their Role in Response to Endocrine Therapy and Clinical Outcome

By  

Oncology, Vol. 82, Iss. 3, 2012-03 ,pp. : 168-174

Karger

Access to resources Recommend Favorite

Use of Palliative Endocrine Therapy in Patients with Hormone Receptor-Positive Distant Metastatic Breast Cancer: How Often, How Effective, How Long?

By  

Oncology, Vol. 90, Iss. 1, 2016-0 ,pp. : 1-9

Karger

Access to resources Recommend Favorite

Clinical Utility of Neoadjuvant Endocrine Therapy for Hormone Receptor Positive Breast Cancer

By  

Reviews on Recent Clinical Trials, Vol. 12, Iss. 2, 2017-05 ,pp. : 67-72

Bentham Science Publishers

Access to resources Recommend Favorite

More treatment options for women with hormone receptor‐positive breast cancer: Guideline update, studies lead to advances in care

By  

CANCER, Vol. 120, Iss. 19, 2014-10 ,pp. : 2939-2940

John Wiley & Sons Inc

Access to resources Recommend Favorite

Physical activity and survival of postmenopausal, hormone receptor–positive breast cancer patients: Results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study

By  

CANCER, Vol. 120, Iss. 18, 2014-09 ,pp. : 2847-2854

John Wiley & Sons Inc

Access to resources Recommend Favorite